Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer

Kuruva, Manohar; Mittal, Bhagwant Rai; Bhoil, Amit; Bhattacharya, Anish; Singh, Gurpreet

doi:10.1097/mnm.0b013e328360d910

Cited by 20 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence level II, strong recommendation. [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] For more information, see Tables 3-5. 3a. 18F-FDG PET/CT should be used in high-risk patients, such as those with inflammatory BC.…”

Section: Resultsmentioning

confidence: 99%

“…11,41,42,46 18F-FDG PET detects distant metastases in more than 20% of patients with locally advanced BC 14,16,20,27,28,31,37,39,40 and changes the initial staging in up to 52% of patients with inflammatory BC. [29][30][31][32] Other authors have reported changes in N stage based on the diagnosis of unsuspected metastatic extraALNs (N3).…”

Section: Diagnostic and Prognostic Impact Of 18f-fdg Pet/ctmentioning

confidence: 99%

“…16,20,23,27 The percentage of patients with extra-ALN involvement detected by PET/CT in locally advanced BC ranges from 10% to 29%. [14][15][16] Moreover, in this setting, given the high prevalence of lymph node involvement (up to 80%), 18F-FDG PET/ CT's high negative predictive value in lymph nodes adds to its usefulness.…”

Section: • •mentioning

confidence: 99%

See 2 more Smart Citations

18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

et al. 2017

View full text Add to dashboard Cite

Current guidelines do not systematically recommend 18F-FDG PET/CT for breast cancer staging; and the recommendations and level of evidence supporting its use in different groups of patients vary among guidelines. This review summarizes the evidence about the role of 18F-FDG PET/CT in breast cancer staging and the therapeutic and prognostic impact accumulated in the last decade. Other related aspects, such as the association of metabolic information with biology and prognosis are considered and evidence-based recommendations for the use of 18F-FDG PET/CT in breast cancer staging are offered. We systematically searched MEDLINE for articles reporting studies with at least 30 patients related to clinical questions following the Problem/Population, Intervention, Comparison, and Outcome framework. We critically reviewed the selected articles and elaborated evidence tables structuring the summarized information into methodology, results, and limitations. The level of evidence and the grades of recommendation for the use of 18F-FDG PET/CT in different contexts are summarized. Level III evidence supports the use of 18F-FDG PET/CT for initial staging in patients with recently diagnosed breast cancer; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a weak recommendation in this population. In patients with locally advanced breast cancer, level II evidence supports the use of 18F-FDG PET/CT for initial staging; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a strong recommendation in this population. In patients with recently diagnosed breast cancer, the metabolic information from baseline 18F-FDG PET/CT is associated with tumor biology and has prognostic implications, supported by level II evidence. In conclusion, 18F-FDG PET/CT is not recommended for staging all patients with early breast cancer, although evidence of improved regional and systemic staging supports its use in locally advanced breast cancer. Baseline tumor glycolytic activity is associated with tumor biology and prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Diagnostic and Prognostic Impact Of 18f-fdg Pet/ctmentioning

confidence: 99%

See 1 more Smart Citation

18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Breast cancer remains the most common type of cancer in women (6). FDG-PET/CT is widely used for detecting local recurrence and local/distant lymph node or organ metastasis in patients with breast cancer.…”

Section: Literature Review and Discussionmentioning

confidence: 99%

“…18 F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is useful in defining the extent of metastatic disease (6,7,8). Herein, we present isolated cutaneous and subcutaneous chest wall metastasis without other distant organ metastasis that were demonstrated with FDG-PET/CT.…”

Section: Introductionmentioning

confidence: 93%

Detection of Isolated Diffuse Cutaneous and Subcutaneous Metastasis of Breast Cancer on FDG-PET/CT

Tamam¹,

Topuz²,

Ekmekçi³

et al. 2015

Mirt

View full text Add to dashboard Cite

Cutaneous metastasis from internal malignancies are rare with a reported incidence between 0.7% and 10%. The most common tumor that metastasize to the skin is breast cancer. We present a 53-year-old woman with a history of bilateral breast cancer who underwent FDG-PET/CT for re-staging, which demonstrated isolated cutaneous and subcutaneous chest wall metastases. Histopathologic verification confirmed invasive ductal carcinoma invasion of the dermis and the lymphatic vessels.

show abstract

Nuclear Medicine in the Diagnosis and Treatment of Breast Cancer

Türkmen

Özkan

2019

Breast Disease

View full text Add to dashboard Cite

Role of 18F-FDG PET/CT in identifying distant metastatic disease missed by conventional imaging in patients with locally advanced breast cancer

Cited by 20 publications

References 5 publications

18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

Detection of Isolated Diffuse Cutaneous and Subcutaneous Metastasis of Breast Cancer on FDG-PET/CT

Nuclear Medicine in the Diagnosis and Treatment of Breast Cancer

Contact Info

Product

Resources

About